NCT05163847View on ClinicalTrials.gov

Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

303

Participants

Timeline

Start Date

June 14, 2022

Primary Completion Date

November 3, 2022

Study Completion Date

November 3, 2022

Conditions
Influenza Vaccine
Interventions
BIOLOGICAL

Cam2020 M2SR H3N2 influenza vaccine

Administered intranasally on Day 1

BIOLOGICAL

Fluzone HD IIV

Administered intramuscularly on Day 1

OTHER

IN Placebo

Administered intranasally on Day 1

OTHER

IM Placebo

Administered intramuscularly on Day 1

Trial Locations (6)

14609

Rochester Clinical Research, Rochester

32127

United Medical Research, Port Orange

44122

Velocity Clinical Research, Beechwood

66219

Johnson County Clin Trials, Lenexa

78613

Velocity Clinical Research, Cedar Park

83642

Velocity Clinical Research, Meridian

Sponsors

Lead Sponsor

FluGen Inc
All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

FluGen Inc

INDUSTRY

NCT05163847 - Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults | Biotech Hunter | Biotech Hunter